In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reed Miller

Deputy Editor

Washington, DC
Reed, deputy editor for commercial and R&D, got his first real job in journalism in 2000 with The Gray Sheet, then part of FDC Reports, based outside of Washington, DC, and has been covering medical technology ever since. His primary focus has been clinical trials and new product development, so he has covered innumerable FDA advisory panel meetings and Medicare coverage decisions. Mixed in to his many years with The Gray Sheet, Reed spent a year in Massachusetts with HCPro in that company’s pharma compliance editorial group, and three years as a reporter for theheart.org, when it was the best news source for cardiologists. In 2015, he’s became deputy editor of Clinica, continuing to track the bewildering and rapidly evolving universe of new medical technology, from IVDs to artificial hearts, from pre-clinical trials to commercialization. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.

Latest From Reed Miller

Medtronic Claims Share Gains In Cardiovascular And Neurostim

The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.

Sales & Earnings Business Strategies

Exec Chat: Steven Mickelsen Helps Acutus Translate Science Into Improved Outcomes

Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.

Exec Chat Appointments

PAVmed Plans Spin-Off And Marketing Push For Lucid Diagnostics

Lucid, which markets the EsoGuard test for Barrett’s esophagus, will become a separate public company, either through an IPO or a business combination with a health care SPAC.

M & A Cancer

Device Week, 19 February 2021 – A Mix Of Insulin Pump; Liquid Biopsy; Transcatheter Device News

In this week’s podcast, Medtech Insight's managing editor Marion Webb discusses Guardant Health’s launch of a new liquid biopsy test to detect early-stage colorectal cancer. Deputy editor Reed Miller discusses Canadian-based Neovasc’s recent funding and what it could mean for its Reducer transcatheter technology. UK-based reporter Barnaby Pickering gives an overview of the fast-growing insulin pump market.

Device Week Digital Health

FDA Approves Shockwave Coronary Intravascular Lithotripsy System

Shockwave Medical received a FDA premarket approval for its C2 coronary intravascular lithotripsy-based calcification remedy and announced its 2020 results, in line with expectations.

Approvals Cardiology

Exact Sciences Acquires Ashion Analytics To Accelerate Sequencing Technology

The addition of the Arizona-based sequencing lab builds on Exact’s recent license of the TARDIS liquid biopsy technology from TGen.

M & A In Vitro Diagnostics
See All
UsernamePublicRestriction

Register